Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica

Internal Medicine

Volumn 46, Issue 19, 2007, Pages 1671-1672

  Okada, Kazumasa ^a   Tsuji, Sadatoshi ^a   Tanaka, Keiko ^b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

IVIG; Neuromyelitis optica

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; IMMUNOGLOBULIN; METHYLPREDNISOLONE; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAPSULA INTERNA; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CERVICAL SPINAL CORD; CONTRAST ENHANCEMENT; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; HEMIPLEGIA; HUMAN; IMMUNOTHERAPY; MALE; MYELITIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PARAPLEGIA; PONS; RELAPSE; URINE RETENTION; VISUAL ACUITY; DOSE RESPONSE; FEMALE; IMMUNOLOGY; RECURRENT DISEASE;

ADULT; AQUAPORIN 4; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; NEUROMYELITIS OPTICA; RECURRENCE;

EID: 35448977649     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.0217     Document Type: Article

References (5)

1. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-1489, 2006.
2. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Clinical predictors of a relapsing course and survival. Neurology 60: 848-853, 2003.
3. Achiron, A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Neurology 50: 398-402, 1998.
4. Tanaka K, Tani T, Tanaka M, et al. Anti-aquaporin 4 antibody in selected Japanese multiple sclerosis patients with long spinal cord lesions. Multiple Sclerosis 2007, DOI: 10.1177/1352458507076976
5. Misu T, Fujihara K, Nakamura M, et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med 209: 269-275, 2006.